Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,392
  • Shares Outstanding, K 36,760
  • Annual Sales, $ 173,250 K
  • Annual Income, $ 68,270 K
  • 36-Month Beta 1.75
  • Price/Sales 0.89
  • Price/Cash Flow 9.38
  • Price/Book 1.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.53
  • Number of Estimates 1
  • High Estimate -0.53
  • Low Estimate -0.53
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -688.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.98 +3.02%
on 09/27/18
4.83 -15.11%
on 10/03/18
-0.30 (-6.82%)
since 09/19/18
3-Month
3.98 +3.02%
on 09/27/18
6.99 -41.34%
on 07/20/18
-2.85 (-41.01%)
since 07/19/18
52-Week
3.98 +3.02%
on 09/27/18
11.93 -65.63%
on 01/25/18
-6.07 (-59.69%)
since 10/19/17

Most Recent Stories

More News
New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorian LPG Ltd. (NYSE:LPG),...

LPG : 7.90 (+0.64%)
AVDL : 4.10 (-2.38%)
TCRD : 7.83 (+0.90%)
REN : 29.88 (+2.54%)
APEI : 29.83 (-1.42%)
PIRS : 5.20 (-1.89%)
Avadel Pharmaceuticals Presents Data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting

Data demonstrate significant improvement in number of nights with one or no nocturic episodes and extended first uninterrupted sleep period in patients suffering from nocturia due to nocturnal polyuria...

AVDL : 4.10 (-2.38%)
Avadel Pharmaceuticals Announces Journal of Urology Publication of Phase 3 Data on NOCTIVA

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, announced today that the Journal of Urology,...

AVDL : 4.10 (-2.38%)
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Operating...

AVDL : 4.10 (-2.38%)
The medical condition 72 percent of Americans don't know about is stealing sleep and disrupting lives, survey shows

Over one-third of Americans wake up more than once per night to urinate due to a condition called nocturia, which can cause daytime tiredness and irritability, impair work productivity, increase risk of...

AVDL : 4.10 (-2.38%)
Avadel Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

Avadel Pharmaceuticals plc (Nasdaq:AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Executive...

AVDL : 4.10 (-2.38%)
WFC : 52.89 (-0.40%)
Avadel Pharmaceuticals PLC Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Avadel Pharmaceuticals PLC Sponsored ADR (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 10:00...

AVDL : 4.10 (-2.38%)
Avadel: 2Q Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Tuesday reported a second-quarter loss of $3.4 million, after reporting a profit in the same period a year earlier.

AVDL : 4.10 (-2.38%)
Avadel Pharmaceuticals to Report Second Quarter 2018 Results

Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018, before the market open. A conference call to discuss these...

AVDL : 4.10 (-2.38%)
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Data demonstrates extended first uninterrupted sleep period in elderly patients

AVDL : 4.10 (-2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 4.35
1st Resistance Point 4.23
Last Price 4.10
1st Support Level 3.99
2nd Support Level 3.87

See More

52-Week High 11.93
Fibonacci 61.8% 8.89
Fibonacci 50% 7.95
Fibonacci 38.2% 7.02
Last Price 4.10
52-Week Low 3.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar